Celius

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Celius

What is Celius? Definition, Type, and Purpose

Property Description
Active ingredient Escitalopram (INN)
Form Film-coated tablet, Oral solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
Common use Modulates mood and anxiety
Origin Synthetic compound

What Type of Medicine is Celius and its Pharmacological Identity?

Celius is a prescription-only medication whose active component is the substance Escitalopram, classified pharmacologically as a Selective Serotonin Reuptake Inhibitor (SSRI) and an antidepressant. Escitalopram is a synthetic compound, chemically recognized as the pure S-enantiomer of the related drug Citalopram, a distinction recognized to enhance its selectivity for the serotonin transporter. As a single-ingredient product, Celius is designed to focus its action specifically on this neurotransmitter pathway. Escitalopram is categorized as a single-ingredient psychotropic agent.

Composition and Available Pharmaceutical Forms

The core composition of Celius contains the active ingredient Escitalopram, prepared as the oxalate salt, alongside pharmaceutical excipients. This formulation is intended for oral administration and is supplied in two primary high-level dosage forms: a film-coated tablet and an oral solution. The availability of both solid and liquid forms provides important flexibility, as the solution allows for dose adjustments or easier consumption for patients who face difficulties swallowing tablets.

General Purpose and Serotonin Modulation

The general purpose of Celius is to influence key signaling pathways in the brain to support the restoration of emotional stability and mental well-being. The drug functions by modulating the levels of the natural neurotransmitter serotonin, a chemical substance critical for maintaining mental balance. By selectively inhibiting the reuptake of serotonin by nerve cells, the medication promotes a sustained presence of this neurotransmitter. This action helps relieve symptoms associated with persistent sadness and excessive worry, achieving its overall goal of providing sustained mood regulation.

Regulatory References

  1. NIH DailyMed: Escitalopram Oxalate Tablet Labeling
  2. NIH MedlinePlus Magazine: How Antidepressants Work (Serotonin context)

What side effects are possible with Celius?

Possible Side Effects and Safety Information

The safety profile of Celius, which contains the active substance Escitalopram, is formally classified by regulatory authorities based on clinical trial and post-marketing data. Adverse reactions are grouped by their reported frequency and the affected System-Organ Class (SOC).

Frequency-Classified Adverse Reactions

Adverse reactions that are frequently reported, typically classified as Common, include gastrointestinal issues such as nausea and constipation, central nervous system effects like insomnia and somnolence (drowsiness), and sexual function disorders, including decreased libido and ejaculatory delay.

Clinically Significant Safety Concerns

The regulatory label documents the potential for serious adverse reactions. These include the risk of Serotonin Syndrome, a potentially life-threatening event. Other documented concerns are QT interval prolongation, which involves a specific cardiac electrical change, and the potential for seizures.

Population and Time-Related Safety

Specific safety considerations are noted for certain populations and periods of use. Close monitoring is required for young adults (aged 24 and under) due to a documented increase in suicidal thoughts and behaviors, particularly during the initial few months of therapy and following dosage changes. Older adults may have an increased susceptibility to conditions such as hyponatremia (low sodium levels). The use of Celius is formally restricted or contraindicated with Monoamine Oxidase Inhibitors (MAOIs) due to the high risk of a serious adverse interaction.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes Celius overdose presentations ranging from typically limited and reversible symptoms to rare, severe systemic events. Symptoms that are commonly reported following acute overdose include lethargy, drowsiness, nausea, vomiting, and pain in the upper abdomen (epigastric pain).

Overdose has the potential for more serious, life-threatening complications, which necessitate immediate medical attention. These rare but severe manifestations can include gastrointestinal bleeding, acute renal failure, respiratory depression, and coma. Anaphylactoid (severe allergic-type) reactions are also noted as a possible, serious risk in the context of overdose, reflecting reported events with therapeutic use.


Emergency Actions

Immediate medical help is required if any severe symptoms occur, such as signs of bleeding, difficulty breathing, or loss of consciousness. Due to the lack of a specific antidote, regulatory guidance stipulates that overdose management consists solely of symptomatic and supportive care. Activated charcoal may be considered for administration within four hours if a potentially significant amount of Celius is suspected to have been ingested. The drug is highly protein-bound, and official information indicates that procedures like hemodialysis are unlikely to be effective in removing the substance.

Therapeutic Uses of Celius

What Celius Treats: Main Uses and Benefits

Celius (Escitalopram) is commonly used in situations involving certain distressing symptoms that may interfere with daily functioning. Its use is generally applied across domains where additional symptomatic support is needed, such as conditions marked by persistent or fluctuating symptom patterns. The primary therapeutic domains include Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) in adults.


The medication is generally relevant for addressing symptom clusters in conditions like Major Depressive Disorder, Generalized Anxiety Disorder, and is commonly used to help with Social Phobia, Panic Disorder, and Premenstrual Dysphoric Disorder (PMDD) in appropriate contexts. It is applied in addressing pervasive symptoms such as uncontrollable worry, chronic tension, persistent sadness, and the debilitating loss of interest or pleasure.

Therapeutic Benefits

“The key benefit is supporting sustained mood regulation, which may help patients cope more steadily with symptom fluctuations and contributes to easing the overall symptom load during periods of heightened symptoms.”

This support contributes to improved comfort during periods of heightened symptoms and provides supportive relief when symptoms interfere with routine activities.



Quick Fact: Relief for Mood and Anxiety Symptoms Celius is commonly used to help with groups of symptoms related to emotional and cognitive distress, including persistent feelings of sadness, excessive worry, and physical tension.


Eligibility and Restrictions for Use

Celius (celecoxib) is a prescription non-steroidal anti-inflammatory drug (NSAID) whose use is strictly governed by regulatory guidelines regarding specific patient populations and conditions.

Contraindicated Populations (Must Not Use)

  • Known Hypersensitivity: Individuals with a documented allergy to celecoxib, any component of the drug product, or to sulfonamides (a chemical group).
  • Aspirin-Sensitive Asthma: Patients with a history of asthma, hives (urticaria), or other allergic-type reactions after taking aspirin or other NSAIDs.
  • Post-CABG Surgery: Contraindicated for the treatment of pain right before or after coronary artery bypass graft (CABG) surgery.

Restrictions and Special Consideration

  • Pregnancy: Use is not recommended in pregnant women starting at 30 weeks of gestation or later due to the risk of fetal harm. Limited use is advised between 20 and 30 weeks of gestation.
  • Organ Impairment: Use should be avoided in patients with severe heart failure, advanced/severe renal impairment, or severe hepatic impairment (Child-Pugh Class C). Monitoring of renal and liver function is necessary for patients with less severe impairment.
  • Pediatric Use: Approved for Juvenile Rheumatoid Arthritis (JRA) in patients two years of age and older.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Celius describes a profile structured by key constraints related to drug metabolism and substance co-ingestion, intended to prevent significant adverse effects.

Interacting Product Category Regulatory Constraint Practical Implication
Other Acetaminophen-Containing Products Do not use concurrently with other products containing this ingredient. The combination is restricted due to a severely increased risk of liver damage.
Oral Anticoagulants (e.g., Warfarin) Use requires consultation with a healthcare professional. The combination requires close professional monitoring of the International Normalized Ratio (INR) due to the potential for altered anticoagulant effects.
Alcohol Avoid or limit consumption; consult a professional if consuming three or more daily alcoholic drinks. Chronic or heavy alcohol use increases the risk of serious liver injury when combined with this product.

This structure establishes strict do-not-combine rules for other medicines containing the same active substance. It also mandates that individuals on blood-thinning medication or those who consume substantial amounts of alcohol must seek professional advice before using Celius. These documented interaction categories serve to manage the risk of overdose, bleeding complications, and dose-related liver toxicity as defined in official government labeling.

Mechanism of Action

How Celius Works

Selective Molecular Targeting of the Serotonin Transporter

The initial action of Celius involves the inhibition of the Serotonin Transporter (SERT), the protein responsible for clearing the neurotransmitter 5 -HT from the synaptic gap. This interaction is highly active because the ingredient, Escitalopram, binds to both the primary transport site (orthosteric site) and a secondary allosteric site. This dual mechanism results in an immediate increase in 5 -HT concentration available for neural signaling.

Chronic Adaptation of Central Regulatory Circuits

Although the molecular block is immediate, the full physiological effect emerges over weeks due to system adaptation; initially, the resulting high 5 -HT stimulates inhibitory autoreceptors, limiting further release. The sustained exposure eventually forces these inhibitory 5 -HT1 A autoreceptors to desensitize, thereby removing the constraint and leading to a pronounced, sustained potentiation of serotonergic transmission that facilitates long-term neuroplastic changes.

Dosage and Administration Information

Celius (Escitalopram) is administered exclusively via the oral route, with the medication available as film-coated tablets in 5 mg, 10 mg (scored), and 20 mg (scored) strengths, as well as an oral solution or drops for measured delivery. The medication is typically taken once daily and can be administered either in the morning or evening, regardless of food intake.

Administration for most adults begins with a dose of 10 mg once daily. If a dose increase is indicated, it typically occurs after a minimum of one week of therapy, with the maximum daily amount restricted to 20 mg. In certain cases, such as the initial management of Panic Disorder, the starting dose may be 5 mg for the first week before increasing to 10 mg. The 10 mg and 20 mg tablets are scored, allowing them to be divided for accurate dose adjustment. The liquid formulation requires careful measurement, and some preparations of oral drops can be mixed with water or certain juices prior to administration.

Specific adjustments are applied for certain patient populations. Older adults (aged 65 and above) and individuals with hepatic impairment are generally administered a reduced maximum recommended dose of 10 mg once daily. Treatment is typically continued as part of a longer-term plan, and discontinuation must be managed by a gradual dose reduction (tapering).

Recent Clinical Evidence

Research Evidence / Overview of studies for Celius


Evidence for use in Chronic Tension Headache (CTH)

Celius was studied for exploring its use in individuals with Chronic Tension Headache (CTH). Research has primarily involved short-term randomized controlled trials (RCTs) conducted on adult participants. Researchers explored outcomes related to physical discomfort, such as the number of headache days per month and patient-reported discomfort levels.

The findings describe patterns observed in the studies over short time intervals, typically up to three months. Data showed patterns related to how participants rated their pain intensity and changes measured in headache frequency. Findings were mixed across the limited available studies, and reported outcomes focused on short-term measurements.


Evidence for use in Mild Cognitive Impairment (MCI) in Older Adults

Celius was evaluated in trials exploring its use in Older Adults with Mild Cognitive Impairment (MCI). Research involved both short-term RCTs and longer observational studies. Studies monitored performance on specific standardized neurocognitive assessments, which are considered outcomes describing acute changes in brain function. Findings indicate patterns related to how scores on these cognitive tests changed over the duration of the studies. Evidence is limited and heterogeneous across the trials, as reported measurements are based on surrogate markers (test scores) rather than functional observations.


What is Still Uncertain about Celius

There is limited information for long-term outcomes across all indications. Follow-up durations were limited, meaning long-term effects are not fully established. Comparative evidence is lacking to understand how the observed patterns relate to other interventions. Furthermore, data for certain groups remain insufficient, including children, adolescents, and older adults with multiple complex health conditions. The results apply only to the specific populations studied, and certainty remains low in several key areas due to small sample sizes and mixed findings.

Key Studies & References National Institute for Health and Care Excellence (NICE): Dementia: assessment, management and support for people living with dementia and their carers

Frequently Asked Questions (FAQ)

Common questions about Celius (FAQ)


Q: What is Celius prescribed for?

Official regulatory documents state that Celius is approved for the treatment of Major Depressive Disorder (MDD) and certain Anxiety Disorders, such as Generalized Anxiety Disorder (GAD). Its general purpose is to modulate mood and anxiety to support mental well-being.


Q: How quickly does Celius usually start working?

According to official product information, the substance reaches its highest level in the bloodstream within a few hours. However, the full therapeutic effect on your symptoms typically takes several weeks to emerge. This delayed effect is due to the time needed for the brain's internal signaling systems to adapt.


Q: Is Celius safe to take with common vitamins or supplements?

Official guidance emphasizes the importance of disclosing all prescription medicines, non-prescription medicines, vitamins, and dietary supplements to the prescribing healthcare provider. This is necessary to determine if any potential interactions may exist.


Q: How long does the effect of Celius last?

Pharmacokinetic studies show that the active substance in Celius has a half-life of approximately 27 to 32 hours. This duration means the substance stays in the body long enough to be effective when taken only once daily.


Q: Is it possible to become dependent on Celius?

Celius is not classified as a controlled substance and is not considered addictive. However, the body can develop a physical dependence on the medication over time. This is why official guidance states that the medicine must always be stopped by using a gradual dose reduction, known as tapering.


Q: Are there any specific foods or drinks to avoid while taking Celius?

Regulatory information indicates that avoiding or limiting alcohol consumption is advised while using Celius due to an increased risk of specific side effects. There are no known restrictions regarding specific foods that must be avoided with this medication.


Q: Can older adults typically use Celius?

Yes, Celius can generally be used by older adults aged 65 and above. However, the official guidance often recommends a reduced maximum daily dose for this population. There is also an increased susceptibility to low sodium levels (hyponatremia) that requires attention.


Q: What happens if I miss a dose of Celius?

Regulatory guidance for a missed dose typically recommends that the dose be skipped and that the next dose be taken at the regularly scheduled time. Patients are advised not to take a double dose to compensate.


Q: Do people typically experience weight changes while on Celius?

Official documents indicate that some individuals may experience changes in appetite while taking this medication. Reported side effects include both the potential for weight gain and, less commonly, loss of appetite.


Q: Can Celius cause skin sensitivity or rashes?

Serious skin reactions are listed as potential adverse effects in regulatory information. These include symptoms like rash, itching, hives, or blistering. Any instance of these reactions is considered serious and is a signal to contact a healthcare professional immediately.


Q: Does taking Celius affect the ability to drive or operate machinery?

Official patient labeling includes a warning against driving a car or operating heavy machinery until an individual is certain of how Celius affects them, due to the risk of drowsiness. This medication may cause drowsiness or potentially affect judgment and movements.


Q: How does Celius interact with birth control pills?

No direct interactions have been widely reported between Celius and common oral contraceptives. However, the medication class to which Celius belongs (SSRIs) has been generally associated with an increased risk of abnormal bleeding.


Q: Is it normal to feel a bit restless after starting Celius?

Restlessness and agitation are specifically listed as potential side effects in official safety documents. These feelings may be particularly noticeable when first starting the medication or following an adjustment in dose.


Q: Can I take Celius if I have high blood pressure?

Celius is generally not contraindicated for high blood pressure alone. However, regulatory warnings note the potential for QT interval prolongation, which is a cardiac electrical change. Individuals with pre-existing heart conditions are noted in the official labeling as requiring caution.


Q: Is there a generic version of Celius available?

Yes, the FDA has approved generic versions of Celius (Escitalopram) tablets. Generic versions contain the exact same active ingredient and are available for prescription.


Q: Are children or teenagers allowed to use Celius?

Official regulatory labels state that Celius is approved for Major Depressive Disorder in adolescents aged 12 to 17. Use in younger children is generally restricted to specific conditions, and close monitoring is necessary for these populations.


Q: Are there any known interactions between Celius and common painkillers?

Yes, caution is required with certain common painkillers. Co-ingestion with Acetaminophen-containing products is restricted, and the use of NSAIDs (like ibuprofen) may increase the risk of bleeding.


Q: Does Celius require any special monitoring or regular blood tests?

Special monitoring is required conditionally for certain patients. Official guidance states that liver and kidney function may need to be monitored in patients with pre-existing impairment, and monitoring is also required for those taking blood-thinning medications.


Q: What is the typical timeframe for a treatment course with Celius?

Official regulatory documents describe Celius as being prescribed as part of a longer-term treatment plan. It is intended for chronic conditions and is not typically used for short-term or temporary purposes.


Q: Is Celius considered a controlled substance?

No, Celius is not classified as a controlled substance under the U.S. Controlled Substances Act. This regulatory classification means it is not subject to the same strict prescribing and storage rules as controlled narcotics.


Q: Can Celius cause headaches?

Headache is listed as a common side effect in official patient safety information. This side effect is typically reported as mild and may resolve after the first few weeks of treatment as the body adjusts to the medication.


Q: Can Celius affect blood sugar levels?

Official guidance indicates that individuals with diabetes may need to have their blood sugar levels monitored more closely while using Celius. The medication may potentially make it more difficult to keep blood sugar stable.


Q: Does Celius interact with herbal remedies like St. John's Wort?

Yes, official drug interaction warnings state that use with the herbal remedy St. John's Wort is generally avoided. This combination can significantly increase the risk of Serotonin Syndrome, a serious safety concern.


Q: Can Celius cause confusion or memory issues?

Confusion, difficulty concentrating, and memory issues have been reported as symptoms. These symptoms are primarily associated with the potential serious side effect of low sodium levels (hyponatremia) documented in official labeling.


Q: Is Celius known to interact with caffeine?

No direct contraindication is listed for caffeine. However, general guidance suggests that the combination of Celius and caffeine may potentially increase central nervous system stimulatory effects, such as nervousness or jitters.

How should Celius be stored and disposed of?

Storage and Disposal Requirements for Celius

The storage and handling of Celius (Escitalopram) must adhere strictly to the conditions defined in official regulatory labeling.

  • Temperature and Protection: The medication must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from excess heat, moisture, and freezing.
  • Container and Stability: Celius must be kept in its original container and the container must be tightly closed. The oral solution formulation has an official in-use limit of 8 weeks after opening, regardless of the bottle's original expiry date.
  • Child Safety: It is required to store the medicine out of the sight and reach of children.
  • Disposal: Unused or expired Celius must be disposed of in accordance with local regulatory requirements, preferably through a drug take-back program. It must not be flushed down the toilet or poured down the sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Celius found in:

A-Z Index: